Latest news with #Anti-MicrobialResistance
Yahoo
4 days ago
- Business
- Yahoo
Molecular Diagnostics at the Point of Care Market Research Report 2025: Comprehensive Five-Year Forecasts - Displacing Frontline Test Protocols and Saving Money
Explore the rapid expansion of the Molecular Diagnostics Point of Care market with our in-depth report. Discover how Point of Care testing is revolutionizing healthcare by reducing costs, enhancing outcomes, and tackling Anti-Microbial Resistance. With a five-year market forecast, this report is essential for understanding potential shifts in frontline test protocols. Stay informed and confident in investment decisions with all data available in Excel format. Gain expertise in your organization at no extra cost. Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics at the Point of Care 2025-2029: By Application, Technology, Place, Product and Country, with Executive Guides and Analysis" has been added to offering. Molecular Diagnostics at the Point of Care is on the brink of unprecedented growth, offering transformative changes in healthcare outcomes and cost-efficiency. This burgeoning market segment is being propelled by advancements in technology and increasing demand for rapid, reliable testing solutions available right at the patient's bedside. Recent data indicates an impressive upward trajectory in market performance, driven in part by major players who are consistently reporting robust growth figures. One of the key catalysts for this surge is the technology's capability to significantly reduce costs while simultaneously enhancing diagnostic outcomes. Importantly, it plays a vital role in combating Anti-Microbial Resistance, presenting a compelling case for its wider adoption. With a market poised to potentially disrupt traditional testing protocols, stakeholders are keen on understanding both the challenges and future outlooks this development entails. This comprehensive report offers an in-depth forecast of the market size over the next five years, enabling stakeholders to align strategies and optimize operations effectively. Equipped with this knowledge, industry experts can gain a competitive edge, leveraging this detailed analysis to inform decision-making processes. Complementing the report, additional specific data and expert assistance are readily available, ensuring that professionals have access to precise and actionable insights without incurring extra charges. For a deeper dive, all report data can be accessed in Excel format upon request, providing a versatile tool for robust investment decisions and accurate valuations. This flexibility ensures that financial assessments and strategic planning are grounded in the most up-to-date information. As the Molecular Diagnostics at Point of Care market continues to evolve, staying informed and prepared is more critical than ever. This report serves as an essential resource for organizations looking to harness these market developments and drive forward-thinking strategies in the healthcare domain. Key Topics Covered: 1 Market Guides1.1 Strategic Situation Analysis1.2 Guide for Executives, Marketing and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors2 Introduction and Market Definition2.1 What are Molecular Diagnostics at the Point of Care?2.2 The Diagnostics Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare Spending3 Instrumentation, Automation and Diagnostic Trends3.1 Instrumentation and Automation3.1.1 Traditional Automation and Centralization3.1.2 The New Automation, Decentralization and Point Of Care3.1.3 Instruments Key to Market Share3.1.4 Bioinformatics Plays a Role3.1.5 PCR Takes Command3.1.6 Next Generation Sequencing Fuels a Revolution3.1.7 NGS Impact on Pricing3.1.8 Whole Genome Sequencing, A Brave New World3.1.9 Companion Diagnostics Blurs Diagnosis and Treatment4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 The Clinical Laboratory Market Segments4.2.1 Traditional Market Segmentation4.2.2 Laboratory Focus and Segmentation4.3 Industry Structure4.3.1 Hospital Testing Share4.3.2 Economies of Scale4.3.2.1 Hospital vs. Central Lab4.3.3 Physician Office Lab's4.3.4 Physician's and POCT5 Profiles of Key MDx Companies5.1 Abbott Laboratories5.2 Abionic5.3 Accelerate Diagnostics5.4 Access Bio5.5 Ador Diagnostics5.6 ADT Biotech5.7 Akonni Biosystems5.8 Alveo Technologies5.9 Anitoa5.10 Applied BioCode5.11 Aureum Diagnostics5.12 Aus Diagnostics5.13 Autonomous Medical Devices5.14 Baebies5.15 Beckman Coulter Diagnostics (Danaher)5.16 Becton, Dickinson and Company5.17 Binx Health5.18 Biocartis5.19 BioFire Diagnostics (bioMerieux)5.20 bioMerieux Diagnostics5.21 Bio-Rad Laboratories, Inc5.22 Bosch Healthcare Solutions GmbH5.23 Cepheid (Danaher)5.24 Credo Diagnostics Biomedical5.25 Cue Health5.26 Curetis (OpGen)5.27 Detect5.28 Diagenode Diagnostics (Hologic)5.29 Diasorin S.p.A.5.30 DNAe5.31 Domus Diagnostics5.32 Enzo Biochem5.33 Eurofins Scientific5.34 Fluxergy5.35 Fusion Genomics.5.36 Genedrive5.37 Genetic Signatures5.38 GenMark Dx (Roche)5.39 Genomadix5.40 Getlabs5.41 Global Access Diagnostics5.42 Grip Molecular Technologies5.43 Hologic5.44 Immunexpress5.45 Inflammatix5.46 Invetech5.47 Iollo5.48 J&J Innovative Medicine5.49 Karius5.50 Lucira Health (Pfizer)5.51 LumiraDx5.52 Maxim Biomedical5.53 Meep5.54 Meridian Bioscience5.55 Millipore Sigma5.56 Molbio Diagnostics5.57 NanoDx5.58 Nanomix5.59 Novacyt5.60 Novel Microdevices5.61 Novus Diagnostics5.62 Nuclein5.63 OnsiteGene5.64 Operon5.65 OraSure Technologies5.66 Oxford Nanopore Technologies5.67 Panagene5.68 Prenetics5.69 Primerdesign (Novacyt)5.70 Prominex5.71 Proof Diagnostics5.72 Qiagen5.73 QuantuMDx5.74 QuidelOrtho5.75 R-Biopharm AG5.76 Response Biomedical5.77 Revvity5.78 Roche Diagnostics5.79 Salignostics5.80 SD Biosensor5.81 Seegene5.82 Sekisui Diagnostics5.83 Siemens Healthineers5.84 Sona Nanotech5.85 SpeeDx5.86 T2 Biosystems5.87 Talis Biomedical5.88 Thermo Fisher Scientific5.89 Uniogen5.90 Veramarx5.91 Veredus Laboratories5.92 XCR Diagnostics5.93 Zhejiang Orient Gene Biotech6 Market Trends6.1 Factors Driving Growth6.1.1 New Genotypes Creating New Markets6.1.2 Aging Population a Boon for All Diagnostics6.1.3 Developing World Driving ID Dx Growth6.1.4 Point of Care - Why Centralization is Losing Steam6.1.5 Self Testing6.1.6 The Need for Speed6.2 Factors Limiting Growth6.2.1 Lower Costs6.2.2 Infectious Disease is Declining6.2.3 Wellness Hurts6.2.4 Economic Growth improves Living Standards7 Molecular Dx - Infectious Disease Recent Developments7.1 Recent Developments - Importance and How to Use This Section7.1.1 Importance of These Developments7.1.2 How to Use This Section7.2 Cubit Dx Secures Funding for High-Sensitivity, Low-Cost Platform7.3 Roche receives FDA clearance for STI at POC7.4 Smartphone-Enabled Platform Transforms POC Testing7.5 Credo Preps MDx System, Multiplex Respiratory Test for US Launch7.6 A low-cost CRISPR-based paper strip test for flu7.7 AMDI Receives Award to Develop 10 Minute POC Respiratory Panel7.8 Roche to Acquire LumiraDx Point-of-Care Testing Tech7.9 DiaSorin to Deliver Updated Instruments, New Assays in 2024/257.10 ReadyGo Diagnostics, Gemina Labs Expand MDx Pact7.11 DiagMetrics Developing Breath Assays7.12 Fortis Life Sciences Acquires IPOC7.13 Domus Diagnostics Wins NIH RADx Tech Contract7.14 Llusern Scientific to Launch POC MDx UTI Panel7.15 Altratech Enters POC MDx Testing Space with Unique Tech7.16 BioMerieux SpotFire MDx POC System Leverages Novel Approach7.17 Katalyst Labs to Distribute ProtonDx Dragonfly Rapid IVD System7.18 LEX Diagnostics Developing Ultra-Fast Low-Cost PCR7.19 Sherlock Biosciences Adds to Infectious Disease Dx Toolkit7.20 NanoDx Prepares for Point-of-Care Commercialization7.21 Paragraf to Study New POC Test to Guide Antibiotic Selection7.22 MicroGEM to Expand 30-Minute RT-PCR System7.23 Startup Detect to Roll Out Next-Gen Molecular Instrument7.24 Diagnostics for the Real World Third-Generation POC Platform7.25 Salignostics Closes Funding Round7.26 Cue Health Targets DTC Market in 20227.27 Grip Molecular Developing Home Respiratory Panel7.28 Mainz Biomed Developing Home ColoAlert Assay7.29 MFB Fertility Closes Series A Financing Round7.30 Home Test Company Prenetics to go Public7.31 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio7.32 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform7.33 Talis Biomedical Discusses Point-of-Care7.34 Roche to Acquire GenMark Diagnostics for $1.8B7.35 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization7.36 Hologic to Acquire Mobidiag7.37 Lucira Health Focuses on User Friendly Approach to Home Testing7.38 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO7.39 Fluidigm Plans 'Durable' Diagnostics, Clinical Business7.40 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M7.41 Mammoth Biosciences Developing Pathogen Detection Tech7.42 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests7.43 Scanogen Developing 90 Minute Infection Test7.44 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection7.45 FDA Provides Self Testing SARS-CoV-2 EAU Guidance7.46 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic7.47 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test7.48 Qiagen Respiratory Panel with Coronavirus Receives CE Mark7.49 Lumos Diagnostics Closes $15M Series A Funding For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Molecular Diagnostics at the Point of Care Market Research Report 2025: Comprehensive Five-Year Forecasts - Displacing Frontline Test Protocols and Saving Money
Explore the rapid expansion of the Molecular Diagnostics Point of Care market with our in-depth report. Discover how Point of Care testing is revolutionizing healthcare by reducing costs, enhancing outcomes, and tackling Anti-Microbial Resistance. With a five-year market forecast, this report is essential for understanding potential shifts in frontline test protocols. Stay informed and confident in investment decisions with all data available in Excel format. Gain expertise in your organization at no extra cost. Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics at the Point of Care 2025-2029: By Application, Technology, Place, Product and Country, with Executive Guides and Analysis" has been added to offering. Molecular Diagnostics at the Point of Care is on the brink of unprecedented growth, offering transformative changes in healthcare outcomes and cost-efficiency. This burgeoning market segment is being propelled by advancements in technology and increasing demand for rapid, reliable testing solutions available right at the patient's bedside. Recent data indicates an impressive upward trajectory in market performance, driven in part by major players who are consistently reporting robust growth figures. One of the key catalysts for this surge is the technology's capability to significantly reduce costs while simultaneously enhancing diagnostic outcomes. Importantly, it plays a vital role in combating Anti-Microbial Resistance, presenting a compelling case for its wider adoption. With a market poised to potentially disrupt traditional testing protocols, stakeholders are keen on understanding both the challenges and future outlooks this development entails. This comprehensive report offers an in-depth forecast of the market size over the next five years, enabling stakeholders to align strategies and optimize operations effectively. Equipped with this knowledge, industry experts can gain a competitive edge, leveraging this detailed analysis to inform decision-making processes. Complementing the report, additional specific data and expert assistance are readily available, ensuring that professionals have access to precise and actionable insights without incurring extra charges. For a deeper dive, all report data can be accessed in Excel format upon request, providing a versatile tool for robust investment decisions and accurate valuations. This flexibility ensures that financial assessments and strategic planning are grounded in the most up-to-date information. As the Molecular Diagnostics at Point of Care market continues to evolve, staying informed and prepared is more critical than ever. This report serves as an essential resource for organizations looking to harness these market developments and drive forward-thinking strategies in the healthcare domain. Key Topics Covered: 1 Market Guides1.1 Strategic Situation Analysis1.2 Guide for Executives, Marketing and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors2 Introduction and Market Definition2.1 What are Molecular Diagnostics at the Point of Care?2.2 The Diagnostics Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare Spending3 Instrumentation, Automation and Diagnostic Trends3.1 Instrumentation and Automation3.1.1 Traditional Automation and Centralization3.1.2 The New Automation, Decentralization and Point Of Care3.1.3 Instruments Key to Market Share3.1.4 Bioinformatics Plays a Role3.1.5 PCR Takes Command3.1.6 Next Generation Sequencing Fuels a Revolution3.1.7 NGS Impact on Pricing3.1.8 Whole Genome Sequencing, A Brave New World3.1.9 Companion Diagnostics Blurs Diagnosis and Treatment4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 The Clinical Laboratory Market Segments4.2.1 Traditional Market Segmentation4.2.2 Laboratory Focus and Segmentation4.3 Industry Structure4.3.1 Hospital Testing Share4.3.2 Economies of Scale4.3.2.1 Hospital vs. Central Lab4.3.3 Physician Office Lab's4.3.4 Physician's and POCT5 Profiles of Key MDx Companies5.1 Abbott Laboratories5.2 Abionic5.3 Accelerate Diagnostics5.4 Access Bio5.5 Ador Diagnostics5.6 ADT Biotech5.7 Akonni Biosystems5.8 Alveo Technologies5.9 Anitoa5.10 Applied BioCode5.11 Aureum Diagnostics5.12 Aus Diagnostics5.13 Autonomous Medical Devices5.14 Baebies5.15 Beckman Coulter Diagnostics (Danaher)5.16 Becton, Dickinson and Company5.17 Binx Health5.18 Biocartis5.19 BioFire Diagnostics (bioMerieux)5.20 bioMerieux Diagnostics5.21 Bio-Rad Laboratories, Inc5.22 Bosch Healthcare Solutions GmbH5.23 Cepheid (Danaher)5.24 Credo Diagnostics Biomedical5.25 Cue Health5.26 Curetis (OpGen)5.27 Detect5.28 Diagenode Diagnostics (Hologic)5.29 Diasorin S.p.A.5.30 DNAe5.31 Domus Diagnostics5.32 Enzo Biochem5.33 Eurofins Scientific5.34 Fluxergy5.35 Fusion Genomics.5.36 Genedrive5.37 Genetic Signatures5.38 GenMark Dx (Roche)5.39 Genomadix5.40 Getlabs5.41 Global Access Diagnostics5.42 Grip Molecular Technologies5.43 Hologic5.44 Immunexpress5.45 Inflammatix5.46 Invetech5.47 Iollo5.48 J&J Innovative Medicine5.49 Karius5.50 Lucira Health (Pfizer)5.51 LumiraDx5.52 Maxim Biomedical5.53 Meep5.54 Meridian Bioscience5.55 Millipore Sigma5.56 Molbio Diagnostics5.57 NanoDx5.58 Nanomix5.59 Novacyt5.60 Novel Microdevices5.61 Novus Diagnostics5.62 Nuclein5.63 OnsiteGene5.64 Operon5.65 OraSure Technologies5.66 Oxford Nanopore Technologies5.67 Panagene5.68 Prenetics5.69 Primerdesign (Novacyt)5.70 Prominex5.71 Proof Diagnostics5.72 Qiagen5.73 QuantuMDx5.74 QuidelOrtho5.75 R-Biopharm AG5.76 Response Biomedical5.77 Revvity5.78 Roche Diagnostics5.79 Salignostics5.80 SD Biosensor5.81 Seegene5.82 Sekisui Diagnostics5.83 Siemens Healthineers5.84 Sona Nanotech5.85 SpeeDx5.86 T2 Biosystems5.87 Talis Biomedical5.88 Thermo Fisher Scientific5.89 Uniogen5.90 Veramarx5.91 Veredus Laboratories5.92 XCR Diagnostics5.93 Zhejiang Orient Gene Biotech6 Market Trends6.1 Factors Driving Growth6.1.1 New Genotypes Creating New Markets6.1.2 Aging Population a Boon for All Diagnostics6.1.3 Developing World Driving ID Dx Growth6.1.4 Point of Care - Why Centralization is Losing Steam6.1.5 Self Testing6.1.6 The Need for Speed6.2 Factors Limiting Growth6.2.1 Lower Costs6.2.2 Infectious Disease is Declining6.2.3 Wellness Hurts6.2.4 Economic Growth improves Living Standards7 Molecular Dx - Infectious Disease Recent Developments7.1 Recent Developments - Importance and How to Use This Section7.1.1 Importance of These Developments7.1.2 How to Use This Section7.2 Cubit Dx Secures Funding for High-Sensitivity, Low-Cost Platform7.3 Roche receives FDA clearance for STI at POC7.4 Smartphone-Enabled Platform Transforms POC Testing7.5 Credo Preps MDx System, Multiplex Respiratory Test for US Launch7.6 A low-cost CRISPR-based paper strip test for flu7.7 AMDI Receives Award to Develop 10 Minute POC Respiratory Panel7.8 Roche to Acquire LumiraDx Point-of-Care Testing Tech7.9 DiaSorin to Deliver Updated Instruments, New Assays in 2024/257.10 ReadyGo Diagnostics, Gemina Labs Expand MDx Pact7.11 DiagMetrics Developing Breath Assays7.12 Fortis Life Sciences Acquires IPOC7.13 Domus Diagnostics Wins NIH RADx Tech Contract7.14 Llusern Scientific to Launch POC MDx UTI Panel7.15 Altratech Enters POC MDx Testing Space with Unique Tech7.16 BioMerieux SpotFire MDx POC System Leverages Novel Approach7.17 Katalyst Labs to Distribute ProtonDx Dragonfly Rapid IVD System7.18 LEX Diagnostics Developing Ultra-Fast Low-Cost PCR7.19 Sherlock Biosciences Adds to Infectious Disease Dx Toolkit7.20 NanoDx Prepares for Point-of-Care Commercialization7.21 Paragraf to Study New POC Test to Guide Antibiotic Selection7.22 MicroGEM to Expand 30-Minute RT-PCR System7.23 Startup Detect to Roll Out Next-Gen Molecular Instrument7.24 Diagnostics for the Real World Third-Generation POC Platform7.25 Salignostics Closes Funding Round7.26 Cue Health Targets DTC Market in 20227.27 Grip Molecular Developing Home Respiratory Panel7.28 Mainz Biomed Developing Home ColoAlert Assay7.29 MFB Fertility Closes Series A Financing Round7.30 Home Test Company Prenetics to go Public7.31 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio7.32 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform7.33 Talis Biomedical Discusses Point-of-Care7.34 Roche to Acquire GenMark Diagnostics for $1.8B7.35 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization7.36 Hologic to Acquire Mobidiag7.37 Lucira Health Focuses on User Friendly Approach to Home Testing7.38 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO7.39 Fluidigm Plans 'Durable' Diagnostics, Clinical Business7.40 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M7.41 Mammoth Biosciences Developing Pathogen Detection Tech7.42 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests7.43 Scanogen Developing 90 Minute Infection Test7.44 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection7.45 FDA Provides Self Testing SARS-CoV-2 EAU Guidance7.46 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic7.47 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test7.48 Qiagen Respiratory Panel with Coronavirus Receives CE Mark7.49 Lumos Diagnostics Closes $15M Series A Funding For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
